Sensei Biotherapeutics Q1 net loss narrows to $8M; SNS-101 Phase 1 dose escalation complete, no DLTs

Sensei Biotherapeutics, Inc.

2024-Q1 EPS reported -$0.32

Net loss of $8.0M for Q1 2024 vs $10.2M in Q1 2023; R&D spend $4.9M, G&A $3.8M.
Cash, cash equivalents and marketable securities $58.1M at March 31, 2024; runway into Q4 2025.
SNS-101 Phase 1/2 dose escalation completed: 16 patients monotherapy, 18 combination; no DLTs observed.
Topline data at ASCO 2024; dose expansion enrolling; end-of-Phase 1 FDA meeting expected by end of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $8.0 million for the quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $8.0 million for the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Net loss was $8.0 million for the quarter ended March 31, 2024

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-134767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.